This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Allen, S. P. Articles by Yacoub, M. H. Search for Related Content PubMed PubMed Citation Articles by Allen, S. P. Articles by Yacoub, M. H.

Circulation, Vol 90, 515-524, Copyright © 1994 by American Heart Association

ARTICLES

Preferential vasoconstriction to cysteinyl leukotrienes in the human saphenous vein compared with the internal mammary artery. Implications for graft performance

SP Allen, AH Chester, MR Dashwood, S Tadjkarimi, PJ Piper and MH Yacoub
Department of Cardiac Surgery, Harefield Hospital, Middlesex, UK.

BACKGROUND: Platelet aggregation with the release of their vasoactive mediators is an important factor contributing to the patency of coronary bypass grafts. However, the role of leukocyte-derived mediators on graft performance is unclear. Leukotrienes (LTs) are proinflammatory mediators released from a variety of leukocytes that possess both vasoactive and mitogenic properties. We have therefore compared the effects of the cysteinyl LTs (C4, D4, and E4) on the human saphenous vein (SV) and human internal mammary artery (IMA). METHODS AND RESULTS: Human SVs from 43 patients (mean age, 58 years) and IMAs from 33 patients (mean age, 57 years) were obtained from individuals undergoing coronary artery bypass surgery for coronary artery disease. The samples were set up in organ baths to record changes in vessel wall tension. In undistended SVs the cysteinyl LTs elicited concentration- dependent contractions. The Emax for LTE4 (4.23 +/- 1.0 mN; n = 6) was significantly less than that observed with either LTC4 (25.7 +/- 4.01 mN; n = 7; P < .001) or LTD4 (26.19 +/- 3.16 mN; n = 7; P < .001). In addition, the LTD4 receptor antagonist ICI 198615 (30 nmol/L) significantly inhibited the LTD4 concentration-response curve but not the LTC4 responses. Furthermore, treatment of the SV with acivicin (0.05 mmol/L), a gamma-glutamyl transpeptidase inhibitor, caused a significant rightward displacement of the LTC4 concentration-response curve. In contrast, LTC4 and LTD4 produced a response in IMAs from only 3 of 29 patients. LTC4 and LTD4 produced small contractions, of which the maximum responses were 3.28 +/- 1.92 mN (n = 5) and 3.12 +/- 1.38 mN (n = 5). LTE4 produced no responses in the IMA. Experiments in which the SV was pretreated with L-NG-monomethyl-L-arginine (L-NMMA; 10(-4) mol/L) or indomethacin (10(-5) mol/L) or was denuded of endothelium had no significant effect on the Emax values for LTE4. Also, the IMA remained unresponsive to cysteinyl leukotrienes after treatment with L- NMMA or indomethacin or endothelium removal. In vitro autoradiography localized specific [3H]-LTC4 and [3H]-LTD4 binding sites (putative receptors) to the smooth muscle cells of both SV and IMA, with greater binding to the SV. CONCLUSIONS: Our data show that there is a preferential contraction to LTs in SV compared with IMA. This difference in smooth muscle cell reactivity to the cysteinyl LTs suggests that endogenous LT production from circulating or infiltrating leukocytes may be an important factor contributing to graft function.

This article has been cited by other articles:

				V. Rudolph and B. A. Freeman Cardiovascular Consequences When Nitric Oxide and Lipid Signaling Converge Circ. Res., September 11, 2009; 105(6): 511 - 522. [Abstract] [Full Text] [PDF]

				M. Back, H. Qiu, J. Z. Haeggstrom, and K. Sakata Leukotriene B4 is an indirectly acting vasoconstrictor in guinea pig aorta via an inducible type of BLT receptor Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H419 - H424. [Abstract] [Full Text] [PDF]

				C. Brink, S.-E. Dahlen, J. Drazen, J. F. Evans, D. W. P. Hay, S. Nicosia, C. N. Serhan, T. Shimizu, and T. Yokomizo International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors Pharmacol. Rev., March 1, 2003; 55(1): 195 - 227. [Abstract] [Full Text] [PDF]

				A. H Chester Mast cells feel the strain Cardiovasc Res, July 1, 2002; 55(1): 13 - 15. [Full Text] [PDF]

				S. Shastri, J. R. McNeill, T. W. Wilson, R. Poduri, C. Kaul, and V. Gopalakrishnan Cysteinyl leukotrienes mediate enhanced vasoconstriction to angiotensin II but not endothelin-1 in SHR Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H342 - H349. [Abstract] [Full Text] [PDF]

				F. Stanke-Labesque, P. Devillier, S. Veitl, F. Caron, J.-L. Cracowski, and G. Bessard Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats Cardiovasc Res, January 1, 2001; 49(1): 152 - 160. [Abstract] [Full Text] [PDF]

				F. Stanke-Labesque, P. Devillier, P. Bedouch, J. L. Cracowski, O. Chavanon, and G. Bessard Angiotensin II-induced contractions in human internal mammary artery: effects of cyclooxygenase and lipoxygenase inhibition Cardiovasc Res, August 1, 2000; 47(2): 376 - 383. [Abstract] [Full Text] [PDF]

				K. Kugiyama, Y. Ota, H. Kawano, H. Soejima, H. Ogawa, S. Sugiyama, H. Doi, and H. Yasue Increase in plasma levels of secretory type II phospholipase A2 in patients with coronary spastic angina Cardiovasc Res, July 1, 2000; 47(1): 159 - 165. [Abstract] [Full Text] [PDF]

				S. Allen, M. Dashwood, K. Morrison, and M. Yacoub Differential Leukotriene Constrictor Responses in Human Atherosclerotic Coronary Arteries Circulation, June 23, 1998; 97(24): 2406 - 2413. [Abstract] [Full Text] [PDF]